Effect of Antihypertensive Agent Choice on Parkinson’s Disease Progression in Patients with Hypertension
Objective: To determine the effect of different classes of antihypertensive medications on Parkinson’s disease progression. Background: Cardiovascular risk factors such as hypertension can worsen Parkinson’s…Apomorphine Sublingual Film’s Efficacy in Elderly Patients with Parkinson’s Disease: Post-hoc Analysis of Study CTH-301
Objective: This study evaluated the efficacy of apomorphine sublingual film (SL-APO) in elderly (≥70 years) and younger (<70 years) patients over the long term. Background:…Treatment with Mucuna pruriens Plus Solo Carbidopa Prescription in Patient Reluctant to Initiation of Traditional Levodopa/Carbidopa Medication
Objective: To see if treatment with Mucuna pruriens 2 capsules (15% levodopa) TID, plus solo carbidopa prescription 25mg TID in patient reluctant to traditional levodopa/carbidopa management could help…Medication therapy in Parkinson’s disease patients: a cross-sectional study at the University Medical Center at Ho Chi Minh City, Vietnam
Objective: To determine the rate of drugs prescribed to treat Parkinson's disease motor symptoms, the rate of the types of drug combinations, and the frequency…Phosphorylated High Mobility Group Box Protein 2 (HMGB2) as a Potential Biomarker for Parkinson’s Disease
Objective: We recently showed that HMGB2 is secreted during ferroptosis and as ferroptosis is involved in the etiology of PD, we have examined the possibility…The Moroccan LRRK2 Registry: Building Resources to Investigate the Penetrance and Phenotype of LRRK2 in North Africans
Objective: The Moroccan LRRK2 Registry aims to establish a comprehensive database integrating clinical data and biosamples to provide valuable insights into the penetrance, phenotype, and…Epigenome-wide and gene-targeted epigenetic profile of isolated REM Sleep Behaviour Disorder: a clinico-molecular study
Objective: Comprehensively characterize the epigenetic profile of isolated REM Sleep Behaviour Disorder (iRBD) using genome-wide and gene-targeted approaches, linking it to clinical measures and phenoconversion.…Facial Blendshape Index(FBI) for Quantification of Hypomimia on Parkinson´s Disease
Objective: To evaluate the validity of ExpressionTracker, an app generating personalized facial blendshapes, for objective quantification of hypomimia in patients with Parkinson’s disease (PD) [1].…Plasma P-tau217 detects Alzheimer’s co-pathology and predicts cognitive decline in Parkinson’s disease
Objective: The objectives of this study are to compare plasma phosphorylated tau-217 (P-tau217) levels in Parkinson’s disease (PD) with versus without Alzheimer’s disease (AD) copathology…Novel Usage of Alpha Synuclein as a Biomarker for Screening Parkinson’s disease at Komfo Anokye Teaching Hospital in Ghana
Objective: This study aimed to assess the use of alpha-synuclein as a biomarker for PD screening and investigate its correlation with disease severity. Background: The…
- « Previous Page
- 1
- …
- 118
- 119
- 120
- 121
- 122
- …
- 181
- Next Page »